Transcriptional inhibition of protease-activated receptor-1 expression by prostacyclin in human vascular smooth muscle cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 28, Issue 3, 2008, Pages 534-540

  Pape, Robert ^a   Rauch, Bernhard H ^a,b   Rosenkranz, Anke C ^a   Kaber, Gernot ^a   Schrör, Karsten ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL DÜSSELDORF   (Germany)

Author keywords

Prostaglandins; Protease activated receptor 1 (PAR 1); RAC1; Smooth muscle; Thrombin

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; 4 AMINO 6 [2 [[4 (DIETHYLAMINO) 1 METHYLBUTYL]AMINO] 6 METHYL 4 PYRIMIDINYL] 2 METHYLQUINOLINE; BUCLADESINE; CICAPROST; FORSKOLIN; GUANOSINE TRIPHOSPHATASE; ILOPROST; ISOBUTYLMETHYLXANTHINE; MESSENGER RNA; PROSTACYCLIN; PROSTAGLANDIN E1; PROSTAGLANDIN E2; PROTEINASE ACTIVATED RECEPTOR 1; RAC1 PROTEIN; RHO FACTOR; RHO KINASE; THROMBIN;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; GENE CONTROL; HUMAN; HUMAN CELL; MITOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION TERMINATION; VASCULAR SMOOTH MUSCLE; ANALYSIS OF VARIANCE; CELL CULTURE; CELL MOTION; CYTOLOGY; DOWN REGULATION; DRUG EFFECT; FLOW CYTOMETRY; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; PHYSIOLOGY; PROBABILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SAPHENOUS VEIN; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; BLOTTING, WESTERN; CELL MOVEMENT; CELLS, CULTURED; DINOPROSTONE; DOWN-REGULATION; EPOPROSTENOL; FLOW CYTOMETRY; GENE EXPRESSION; HUMANS; ILOPROST; IMMUNOHISTOCHEMISTRY; MUSCLE, SMOOTH, VASCULAR; PROBABILITY; RECEPTOR, PAR-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SAPHENOUS VEIN; SIGNAL TRANSDUCTION; TRANSCRIPTION, GENETIC;

EID: 40749138656     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/ATVBAHA.107.159483     Document Type: Article

References (44)

1. Patterson C, Stouffer GA, Madamanchi N, Runge MS. New tricks for old dogs: nonthrombotic effects of thrombin in vessel wall biology. Circ Res. 2001;88:987-997.
2. Bretschneider E, Spanbroek R, Lötzer K, Habenicht AJ, Schrör K. Evidence for functionally active protease-activated receptor-3 (PAR-3) in human vascular smooth muscle cells. Thromb Haemost. 2003;90: 704-709.
3. Ruf W, Dorfleutner A, Riewald M. Specificity of coagulation factor signaling. J Thromb Haemost. 2003;1:1495-1503.
4. Coughlin SR. How the protease thrombin talks to cells. Proc Natl Acad Sci U S A. 1999;96:11023-11027.
5. Vu TK, Hung DT, Wheaton VI, Coughlin SR. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell. 1991;64:1057-1068.
6. Hoxie JA, Ahuja M, Belmonte E, Pizarro S, Parton R, Brass LF. Internalization and recycling of activated thrombin receptors. J Biol Chem. 1993;268:13756-13763.
7. Hein L, Ishii K, Coughlin SR, Kobilka BK. Intracellular targeting and trafficking of thrombin receptors. A novel mechanism for resensitization of a G protein-coupled receptor. J Biol Chem. 1994;269:27719-27726.
8. Woolkalis MJ, DeMelfi TM Jr, Blanchard N, Hoxie JA, Brass LF. Regulation of thrombin receptors on human umbilical vein endothelial cells. J Biol Chem. 1995;270:9868-9875.
9. Connolly AJ, Ishihara H, Kahn ML, Farese RV Jr, Coughlin SR. Role of the thrombin receptor in development and evidence for a second receptor. Nature. 1996;381:516-519.
10. Barnes JA, Singh S, Gomes AV. Protease activated receptors in cardiovascular function and disease. Mol Cell Biochem. 2004;263:227-239.
11. Steinberg SF. The cardiovascular actions of protease-activated receptors. Mol Pharmacol. 2005;67:2-11.
12. Cheung WM, D'Andrea MR, Andrade-Gordon P, Damiano BP. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler Thromb Vasc Biol. 1999;19:3014-3024.
13. Takada M, Tanaka H, Yamada T, Ito O, Kogushi M, Yanagimachi M, Kawamura T, Musha T, Yoshida F, Ito M, Kobayashi H, Yoshitake S, Saito I. Antibody to thrombin receptor inhibits neointimal smooth muscle cell accumulation without causing inhibition of platelet aggregation or altering hemostatic parameters after angioplasty in rat. Circ Res. 1998; 82:980-987.
14. Belton O, Byrne D, Kearney D, Leahy A, Fitzgerald DJ. Cyclooxygenase-1 and -2-dependent prostacyclin formation in patients with atherosclerosis. Circulation. 2000;102:840-845.
15. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, Belton O. Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther. 2002;300:393-398.
16. Schonbeck U, Sukhova GK, Graber P, Coulter S, Libby P. Augmented expression of cyclooxygenase-2 in human atherosclerotic lesions. Am J Pathol. 1999;155:1281-1291.
17. Rimarachin JA, Jacobson JA, Szabo P, Maclouf J, Creminon C, Weksler BB. Regulation of cyclooxygenase-2 expression in aortic smooth muscle cells. Arterioscler Thromb. 1994;14:1021-1031.
18. Bishop-Bailey D, Pepper JR, Larkin SW, Mitchell JA. Differential induction of cyclooxygenase-2 in human arterial and venous smooth muscle: role of endogenous prostanoids. Arterioscler Thromb Vasc Biol. 1998;18:1655-1661.
19. Schrör K. Prostacyclin (Prostaglandin I2) and Atherosclerosis. In: Rubanyi GM, Dzau V, eds. The endothelium in clinical practice: source and target of novel concepts and therapeutics. New York: Marcel Dekker. 1997:1-44.
20. Weiss HJ, Turitto VT. Prostacyclin (prostaglandin I2, PGI2) inhibits platelet adhesion and thrombus formation on subendothelium. Blood. 1979;53:244-250.
21. Grosser T, Bönisch D, Zucker TP, Schrör K. Iloprost-induced inhibition of proliferation of coronary artery smooth muscle cells is abolished by homologous desensitization. Agents Actions Suppl. 1995;45:85-91.
22. Hara S, Morishita R, Tone Y, Yokoyama C, Inoue H, Kaneda Y, Ogihara T, Tanabe T. Overexpression of prostacyclin synthase inhibits growth of vascular smooth muscle cells. Biochem Biophys Res Commun. 1995;216: 862-867.
23. Blindt R, Bosserhoff AK, vom Dahl J, Hanrath P, Schrör K, Hohlfeld T, Meyer-Kirchrath J. Activation of IP and EP(3) receptors alters cAMPdependent cell migration. Eur J Pharmacol. 2002;444:31-37.
24. Debey S, Kirchrath L, Schrör K, Meyer-Kirchrath J. Iloprost downregulates the expression of the growth regulatory gene Cyr61 in human vascular smooth muscle cells. Eur J Pharmacol. 2003;474:161-164.
25. Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schrör K, Weber AA. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2-derived prostaglandins. Circ Res. 2005;96:e1-e6.
26. Fetalvero KM, Shyu M, Nomikos AP, Chiu YF, Wagner RJ, Powell RJ, Hwa J, Martin KA. The prostacyclin receptor induces human vascular smooth muscle cell differentiation via the protein kinase A pathway. Am J Physiol Heart Circ Physiol. 2006;290:H1337-H1346.
27. Meyer-Kirchrath J, Debey S, Glandorff C, Kirchrath L, Schrör K. Gene expression profile of the Gs-coupled prostacyclin receptor in human vascular smooth muscle cells. Biochem Pharmacol. 2004;67:757-765.
28. Yufu T, Hirano K, Bi D, Hirano M, Nishimura J, Iwamoto Y, Kanaide H. Rac1 regulation of surface expression of protease-activated receptor-1 and responsiveness to thrombin in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:1506 -1511.
29. Rauch BH, Bretschneider E, Braun M, Schrör K. Factor Xa releases matrix metalloproteinase-2 (MMP-2) from human vascular smooth muscle cells and stimulates the conversion of pro-MMP-2 to MMP-2: role of MMP-2 in factor Xa-induced DNA synthesis and matrix invasion. Circ Res. 2002;90:1122-1127.
30. Rauch BH, Millette E, Kenagy RD, Daum G, Fischer JW, Clowes AW. Syndecan-4 is required for thrombin-induced migration and proliferation in human vascular smooth muscle cells. J Biol Chem. 2005;280: 17507-17511.
31. Winer J, Jung CK, Shackel I, Williams PM. Development and validation of real-time quantitative reverse transcriptase-polymerase chain reaction for monitoring gene expression in cardiac myocytes in vitro. Anal Biochem. 1999;270:41-49.
32. Gao Y, Dickerson JB, Guo F, Zheng J, Zheng Y. Rational design and characterization of a Rac GTPase-specific small molecule inhibitor. Proc Natl Acad Sci U S A. 2004;101:7618-7623.
33. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, Tamakawa H, Yamagami K, Inui J, Maekawa M, Narumiya S. Calcium sensitization of smooth muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-994.
34. Galis ZS, Kranzhofer R, Fenton JW, 2nd, Libby P. Thrombin promotes activation of matrix metalloproteinase-2 produced by cultured vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 1997;17:483-489.
35. Sokolova E, Grishina Z, Buhling F, Welte T, Reiser G. Protease-activated receptor-1 in human lung fibroblasts mediates a negative feedback down-regulation via prostaglandin E2. Am J Physiol Lung Cell Mol Physiol. 2005;288:L793-L802.
36. Zacharias U, Xu Y, Hagege J, Sraer JD, Brass LF, Rondeau E. Thrombin, phorbol ester, and cAMP regulate thrombin receptor protein and mRNA expression by different pathways. J Biol Chem. 1995;270:545-550.
37. Bulin C, Albrecht U, Bode JG, Weber AA, Schrör K, Levkau B, Fischer JW. Differential effects of vasodilatory prostaglandins on focal adhesions, cytoskeletal architecture, and migration in human aortic smooth muscle cells. Arterioscler Thromb Vasc Biol. 2005;25:84-89.
38. Kiriyama M, Ushikubi F, Kobayashi T, Hirata M, Sugimoto Y, Narumiya S. Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997;122:217-224.
39. Rochdi MD, Laroche G, Dupre E, Giguere P, Lebel A, Watier V, Hamelin E, Lepine MC, Dupuis G, Parent JL. Nm23-H2 interacts with a G protein-coupled receptor to regulate its endocytosis through an Rac1dependent mechanism. J Biol Chem. 2004;279:18981-18989.
40. Tkachenko E, Lutgens E, Stan RV, Simons M. Fibroblast growth factor 2 endocytosis in endothelial cells proceed via syndecan-4-dependent activation of Rac1 and a Cdc42-dependent macropinocytic pathway. J Cell Sci. 2004;117:3189-3199.
41. Seasholtz TM, Majumdar M, Kaplan DD, Brown JH. Rho and Rho kinase mediate thrombin-stimulated vascular smooth muscle cell DNA synthesis and migration. Circ Res. 1999;84:1186-1193.
42. Li F, Baykal D, Horaist C, Yan CN, Carr BN, Rao GN, Runge MS. Cloning and identification of regulatory sequences of the human thrombin receptor gene. J Biol Chem. 1996;271:26320-26328.
43. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene. 2003;22:3130-3137.
44. Wong DL, Anderson LJ, Tai TC. Cholinergic and peptidergic regulation of phenylethanolamine N-methyltransferase gene expression. Ann N Y Acad Sci. 2002;971:19-26.